

Peter L. Kolominsky-Rabas

CURRICULUM VITAE

Personal Details

Name: Peter L. Kolominsky-Rabas
Education: MD, PhD, MBA in Health Economics & Outcomes Research

Professional experience

Current position:

- NDA HTA Advisory Board Member
- Professor and Director of the Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health, University of Erlangen-Nürnberg, Germany

Previous positions:

- Head of Department 'Health Economics and Outcomes Research' in the Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne, the main scientific advisory body to the Federal Government and the Federal Joint Committee (GBA) representing the German Statutory Health Insurance System. During this time Prof. Kolominsky-Rabas was deeply involved in shaping the HTA conception for the German health care system and strategic reimbursement matters. He established a world-wide advisory network including leading health economists and HTA agencies such as NICE (UK), HAS (France), Institute for Clinical Evaluative Sciences, (Canada) and LBI-HTA (Austria). Prof. Kolominsky-Rabas is one of few experts in this field and is advising national health institutions in Germany as well as several government agencies in the European Union.

Area of Expertise

- Prof. Kolominsky-Rabas has research interests in the fields of:
 - Health Technology Assessment (HTA)
 - Market Access
 - Reimbursement

Major Projects

- Since 2010 coordinator of HTA program within the National Cluster 'Centre of Excellence for Health Technology' funded by the German Federal Ministry of Research (BMBF)
- Since 2000 Principal Investigator of the Erlangen Stroke Registry as part of the Federal Health Reporting (GBE) funded by the German Federal Ministry of Health (BMG)
- eHealth Monitor – telemedicine support of citizens with dementia and their careers in Europe funded by the European Commission

Associations

- Member of the **Innovative Medicines Initiative (IMI)**. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA and is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
- Member of the **European Healthcare Innovation Leadership Network** testing multi-stakeholder consultations in early-stage drug development. This network involves HTA experts, clinicians, patient representatives, payers, regulators and drug developers from France, Germany, Italy, the Netherlands, Sweden, the United Kingdom and the European Medicines Agency (EMA).

Scientific Background

- 1990 M.D. degree 'summa cum laude' from University of Muenster
- 1989-1997 Clinical training in Neurology, Psychiatry, Radiology and Rehabilitation, University Hospital Erlangen
- 1998-2000 Founder and Head of the population-based Erlangen Stroke Registry
- 2000 Senior Consultant in Clinical Neurology
- 2001-2004 Managing Director of the Interdisciplinary Centre for HTA & Public Health
- 2003 Ph.D. in 'Epidemiology and Outcomes Research', University of Erlangen
- 2003-to date Senior Lecturer in Public Health & Outcomes Res., University of Erlangen
- 2007 M.B.A. from the University of Bayreuth
- 2005-2008 Head of Department 'Health Economics and Outcomes Research', Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne
- 2009-to date Director of the Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health, University of Erlangen-Nuremberg, Germany

Publications

Full list available upon request.